|
1) Okamura H, Tsutsui H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995; 378: 88-91
|
|
|
|
2) Tanaka H, Miyazaki N, Oashi K, et al. IL-18 might reflect disease activity in mild and moderate asthma exacerbation. J Allergy Clin Immunol. 2001; 107: 331-6
|
|
|
|
|
|
3) Petersen A, Penkowa M, Iversen M, et al. Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung. 2007; 185: 161-71
|
|
|
|
|
|
4) Antoniou K, Alexandrakis M, Sfiridaki K, et al. Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasc Diffuse Lung Dis. 2004; 21: 105-10
|
|
|
|
|
|
5) Kitasato Y, Hoshino T, Okamoto M, et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2004; 31: 619-25
|
|
|
|
|
|
6) Hoshino T, Wiltrout R, Young H. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999; 162: 5070-7
|
|
|
|
|
|
7) Yoshimoto T, Tsutsui H, Tominaga K, et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A. 1999; 96: 13962-6
|
|
|
|
|
|
8) Yoshimoto T, Min B, Sugimoto T, et al. Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4＋ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J Exp Med. 2003; 197: 997-1005
|
|
|
|
|
|
9) Tsutsui H, Yoshimoto T, Hayashi N, et al. Induction of allergic inflammation by interleukin-18 in experimental animal models. Immunol Rev. 2004; 202: 115-38
|
|
|
|
|
|
10) Sugimoto T, Ishikawa Y, Yoshimoto T, et al. Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J Exp Med. 2004; 199: 535-45
|
|
|
|
|
|
11) Terada M, Tsutsui H, Imai Y, et al. Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced by Staphylococcus aureus product in mice. Proc Natl Acad Sci U S A. 2006; 103: 8816-21
|
|
|
|
|
|
12) Hata H, Yoshimoto T, Hayashi N, et al. IL-18 together with anti-CD3 antibody induces human Th1 cells to produce Th1- and Th2-cytokines and IL-8. Int Immunol. 2004; 16: 1733-9
|
|
|
|
|
|
13) Takaoka A, Tanaka Y, Tsuji T, et al. A critical role for mouse CXC chemokine(s) in pulmonary neutrophilia during Th type 1-dependent airway inflammation. J Immunol. 2001; 167: 2349-53
|
|
|
|
|
|
14) Busse WW, Lemanske RJ. Asthma. N Engl J Med. 2001; 344: 350-62
|
|
|
|
|
|
15) Hayashi N, Yoshimoto T, Izuhara K, et al. Th1 cells stimulated with OVA and IL-18 induce both airway hyper responsiveness and lung fibrosis by production of IFN-γ and IL-13. Proc Natl Acad Sci U S A. 2007; 104: 14765-70
|
|
|
|
|
|
16) Ho L, Davis M, Denison A, et al. Reduced interleukin-18 levels in BAL specimens from patients with asthma compared to patients with sarcoidosis and healthy control subjects. Chest. 2002; 121: 1421-6
|
|
|
|
|
|
17) 林 伸樹, 中西憲司. 気管支喘息病態とIL-18. In: 奥村 康, 他編. Annual Review 免疫 2007. 東京: 中外医学社; 2007. p. 294-300
|
|
|
|
|
|
18) Maecker H, Hansen G, Walter D, et al. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol. 2001; 166: 959-65
|
|
|
|
|
|
19) Hofstra C, Van Ark I, Hofman G, et al. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J Immunol. 1998; 161: 5054-60
|
|
|
|
|
|
20) Wild J, Sigounas A, Sur N, et al. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol. 2000; 164: 2701-10
|
|
|
|
|
|
21) Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998; 161: 3400-7
|
|
|
|
|
|
22) Okamoto M, Kato S, Oizumi K, et al. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood. 2002; 99: 1289-98
|
|
|
|
|
|
23) Hoshino T, Kato S, Oka N, et al. Pulmonary inflammation and emphysema: Role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med. 2007; 176: 49-62
|
|
|
|
|
|
24) Segel M, Izbicki G, Cohen P, et al. Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2003; 285: L1255-62
|
|
|
|
|
|
25) Nakatani-Okuda A, Ueda H, Kashiwamura S, et al. Protection against bleomycin-induced lung injury by IL-18 in mice. Am J Physiol Lung Cell Mol Physiol. 2005; 289: L280-7
|
|
|
|
|
|
26) Wang Z, Zheng T, Zhu Z, et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000; 192: 587-600
|
|
|
|
|
|
27) Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000; 106: 1081-93
|
|
|
|
|
|
28) Kang M, Homer R, Gallo A, et al. IL-18 is induced and IL-18 receptor alpha plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammat. J Immunol. 2007; 178: 1948-59
|
|
|
|
|
|
29) Akgun M, Saglam L, Kaynar H, et al. Serum IL-18 levels in tuberculosis: comparison with pneumonia, lung cancer and healthy controls. Respirology. 2005; 10: 295-9
|
|
|
|
|
|
30) Pechkovsky D, Goldmann T, Vollmer E, et al. Interleukin-18 expression by alveolar epithelial cells type II in tuberculosis and sarcoidosis. FEMS Immunol Med Microbiol. 2006; 46: 30-8
|
|
|
|
|
|
31) Kieszko R, Krawczyk P, Jankowska O, et al. The clinical significance of interleukin 18 assessment in sarcoidosis patients. Respir Med. 2007; 101: 722-8
|
|
|
|
|
|
32) Naumnik W, Chyczewska E, Kovalchuk O, et al. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Rocz Akad Med Bialymst. 2004; 49: 246-51
|
|
|
|
|
|
33) Paterson G, Blue C, Mitchell T. Role of interleukin-18 in experimental infections with Streptococcus pneumoniae. J Med Microbiol. 2005; 54: 323-6
|
|
|
|
|
|
34) Nakasone C, Kawakami K, Hoshino T, et al. Limited role for interleukin-18 in the host protection response to pulmonary infection with Pseudomonas aeruginosa in mice. Infect Immun. 2004; 72: 6176-80
|
|
|
|
|
|
35) Liu B, Mori I, Hossain M, et al. Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J Gen Virol. 2004; 85: 423-8
|
|
|
|
|